title: Effects of fialuridine on hepatitis B immune globulin pharmacokinetics following orthotopic liver transplant for chronic hepatitis B viral-induced cirrhosis.
authors.affiliation: Department of Surgery, University of Virginia Health Sciences, Charlottesville 22908.
authors.forename: R W
authors.initials: RW
authors.lastname: McGory
authors.forename: M B
authors.initials: MB
authors.lastname: Ishitani
authors.forename: W M
authors.initials: WM
authors.lastname: Oliveira
authors.forename: W C
authors.initials: WC
authors.lastname: Stevenson
authors.forename: R C
authors.initials: RC
authors.lastname: Dickson
authors.forename: S H
authors.initials: SH
authors.lastname: Caldwell
authors.forename: T L
authors.initials: TL
authors.lastname: Pruett
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000628:therapy*; D006512:Hepatitis B Core Antigens / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000302:isolation & purification*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000601:surgery*; D016031:Liver Transplantation / Q000473:pathology; D008297:Male
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D016756:Immunoglobulins, Intravenous; D001086:Arabinofuranosyluracil; C043457:fialuridine